top of page
News, Events and Updates
Search
Feb 10, 2009
Anavex Appoints Leading Alzheimer’s Disease Expert Dr. Mark Smith to Scientific Advisory Board
Jan 30, 2009
Anavex Scales Up Synthesis of ANAVEX 2-73 for Phase 1 Alzheimer’s Disease Study
Dec 17, 2008
Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer’s Compound ANAVEX 1-41
Dec 4, 2008
Anavex Presents Potent Neuroprotective Effects of ANAVEX 1-41 at Neuroscience 2008
Sep 1, 2008
Anavex Completes Successful Preclinical Studies on Lead Alzheimer’s Drug Candidate
Jul 29, 2008
Anavex Presents Neuroprotective Effects of ANAVEX 1-41 at the International Conference on AD 2008
Jun 23, 2008
Anavex Life Sciences Corp. Will Present New Findings at the International Conference on AD 2008
Jun 2, 2008
Anavex Further Strengthens Board of Directors
May 20, 2008
Anavex Announces Appointment of Oncology Specialist to Board of Directors
Apr 9, 2008
Low density of sigma-1 receptors in early Alzheimer’s disease.
Mar 9, 2008
ANAVEX 7-1037 Reduces Rate of Cancer Tumor Growth 69% in Pre-Clinical Studies, Compared to Currently
46
47
48
49
50
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
